Saturday, August 17, 2019

 


Acasti Pharma Inc
(TSX-V: ACST.VN) Add to Watchlist
$2.540
+0.210 (+9.01%)
as of Aug 16, 2019

Last 2.540
Change +0.210 (+9.01%)
Open 2.360
Prev. Close 2.330
Today's Range
2.360 2.600
52wk Range
0.590 3.880
Volume 107,655
Avg Volume 375,926

Recent Headlines
Achieved 100% Patient Randomization in both TRILOGY trials  (full story)
ACST.VN: 2.540 (+0.210), ACST: 1.91 (+0.16)
Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announ  (full story)
ACST.VN: 2.540 (+0.210), ACST: 1.91 (+0.16)
Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today annou  (full story)
ACST.VN: 2.540 (+0.210), ACST: 1.91 (+0.16)
Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today commen  (full story)
ACST.VN: 2.540 (+0.210), ACST: 1.91 (+0.16)
According to a report from Grand View Research, the global diabetic foot ulcer treatment market size is expected to reach a value of USD 6.82 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.2% during the forecast period. "Rising prevalence of diabe  (full story)
ACST.VN: 2.540 (+0.210), OTLK: 2.00 (-0.05), MTP: 1.34 (+0.13), HOTH: 5.42 (+0.16), TEVA: 6.41 (+0.25), ACST: 1.91 (+0.16)
Performance Comparison
Name Today 3-Month 1-Year
ACST.VN +9.01% +117.09% +323.33%
$TXCX +0.86% -0.39% -0.47%
$TXSC +0.96% -0.77% -0.28%
DJIA +1.20% +0.64% +1.28%
S&P 500 +1.44% +1.59% +1.69%

Key Statistics
Annual EPS -0.870
Dividend & Yield -- (--)
P/E Ratio N/A
Market Capitalization, $K 215,437
Weighted Alpha +118.70
Standard Deviation +0.89
Profit Margin --
Beta -0.209

Growth Rates
YTD +122.81%
1-Year +316.39%
© 2019 Market data provided and hosted by Barchart Market Data Solutions. Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.